Silymarin Encyclopedia — Scientific Background

What Is Silymarin?

Silymarin (CAS 65666-07-1) is a standardized flavonolignan complex extracted from the seeds of Silybum marianum (L.) Gaertn., commonly known as milk thistle. It is a mixture of flavonolignans consisting primarily of silybin A and B (also known as silibinin), isosilybin A and B, silychristin, isosilychristin, and silydianin. Silybin accounts for 60–70% of the total silymarin content and is considered the primary marker compound responsible for its pharmacological action. The extract is typically standardized to contain 70%–80% silymarin by HPLC, calculated as silybin.

Botanical Source

Silymarin is extracted from the dried ripe fruit (seeds) of Silybum marianum (L.) Gaertn., a plant in the Asteraceae family native to the Mediterranean region. The active complex is a lipophilic extract from the seeds, composed of three isomer flavonolignans (silybin, silydianin, and silychristine), collectively known as silymarin. Silymarin is the most frequently extracted from the whole pulverized seeds, or from the seed cake obtained by cold pressing the oil.

Mechanisms of Action

Hepatoprotective Mechanisms — Multiple Pathways

Silymarin‘s hepatoprotective activity operates through several complementary mechanisms:

• Hepatotoxin Binding Inhibition — Inhibition of hepatotoxin binding to receptor sites on the hepatocyte membrane

• Glutathione Enhancement — Reduction of glutathione oxidation to enhance its level in the liver and intestine

• Antioxidant Activity — Scavenging of prooxidant free radicals and inhibition of lipid peroxidation

• Protein Synthesis Stimulation — Stimulation of ribosomal RNA polymerase and subsequent protein synthesis, leading to enhanced hepatocyte regeneration

• Membrane Stabilization — Stabilization of hepatocyte membranes and prevention of membrane permeability changes

Antioxidant Defense

Silymarin and its active constituent, silybin, work as antioxidants scavenging free radicals and inhibiting lipid peroxidation. They protect against genomic injury, increase hepatocyte protein synthesis, decrease the activity of tumor promoters, stabilize mast cells, chelate iron, and slow calcium metabolism.

Anti-Fibrotic Activity

Silymarin and silibinin delayed hepatic stellate cell activation, probably due to inhibition of NF-κB activation. The beneficial effect of high doses of silymarin (200 mg/kg) on fibrosis may be due to promotion of hepatic stellate cell apoptosis. Silymarin also controls inflammation, enhances glucuronidation, and protects against glutathione depletion.

Anti-Inflammatory Effects

Silymarin acts through antioxidative, anti-lipid peroxidative, antifibrotic, anti-inflammatory, membrane stabilizing, immunomodulatory, and liver regenerating mechanisms. It helps in regenerating liver tissue, controls inflammation, and protects against glutathione depletion.

The Bioavailability Challenge

Despite its broad pharmacological potential, silymarin presents significant formulation challenges. The compound has poor water solubility and its oral absorption is only about 23–47%, leading to an extremely low oral bioavailability of 0.73%. Silymarin undergoes extensive phase II metabolism in the intestine and liver, primarily into glucuronide and sulfate conjugates, which further limits its systemic exposure and target tissue delivery.

These limitations have driven the development of advanced delivery systems, including phytosomes, liposomes, nanoparticles, and solid dispersions. Among these, liposomal encapsulation has emerged as one of the most effective strategies for enhancing silymarin bioavailability and hepatoprotective efficacy.

Liposomal Silymarin

Liposomal encapsulation of silymarin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the silymarin molecule, forming a protective shell that enhances solubility, stability, and cellular uptake. This delivery system:

• Achieves a 3.5-fold higher oral bioavailability compared to silymarin suspension

• Enhances hepatoprotection efficacy by 1.5-fold in vitro

• Prevents ROS production by 10-fold in LPS-induced macrophages

• Provides targeted delivery to hepatocytes and inflammatory cells

• Achieves 4.8-fold increase in AUC₀–ₜ with bile salt-containing liposomes

A lecithin-based phytosomal-liposomal formulation of silymarin was prepared by film hydration method and showed maximum entrapment (55%) for a lecithin–cholesterol ratio of 6:1. Comparative release profile of the formulation was better than silymarin at pH 1.2 and pH 7.4. In vitro studies showed better hepatoprotection efficacy for the formulation and better prevention of ROS production compared to silymarin. In an in vivo paracetamol-induced hepatotoxicity model in Wistar rats, the formulation was found more efficacious than silymarin suspension in protecting the liver and the associated inflammatory conditions.

Clinical Evidence

Liver Disease — Cochrane Review

A 2007 Cochrane review of 13 randomized clinical trials assessed milk thistle in 915 patients with alcoholic and/or hepatitis B or C virus liver diseases. Silymarin has been approved in different doses for the treatment or adjuvant therapy for liver disorders by regulatory authorities of different countries.

NAFLD/MASLD — Cochrane Meta-Analysis

A 2025 Cochrane meta-analysis included 17 randomized clinical trials with 2,069 participants having metabolic dysfunction–associated steatotic liver disease (MASLD). The benefits and harms of silymarin in adults with MASLD remain unclear, though silymarin monotherapy was compared with no intervention or placebo.

Type 2 Diabetes

A few early studies suggest that taking 200 mg of silymarin three times per day for 4 months with conventional treatment may have health benefits in people with type 2 diabetes, including decreased blood glucose and improved lipid profiles.

Clinical Trial in NAFLD and Metabolic Syndrome

A prospective single-arm study evaluated silymarin with lifestyle intervention in NAFLD and metabolic syndrome patients. Patients were prescribed standard of care (diet and physical exercise) and one capsule of 140 mg of silymarin thrice daily for 6 months. Silymarin extracted from Silybum marianum is effective and well tolerated in patients with liver disorders.

Safety and Regulatory

Silymarin is generally well tolerated. Taken in appropriate doses, oral use of milk thistle appears to be safe. The most common side effects are gastrointestinal issues, such as diarrhea, constipation, nausea, vomiting, and abdominal bloating, as well as itchiness and headache. Silibinin is very well tolerated, and no serious side effects were observed in clinical or in vivo studies.

Regulatory status varies by region:

• United States — Milk thistle extract is regulated as a dietary supplement. The FDA does not require registration or approval for dietary supplements. Milk thistle extract is generally recognized as safe for intended uses (GRAS Self-Determined).

• European Union — In 2018, the European Medicines Agency (EMA) evaluated Silybum marianum (L.) Gaertn., fructus for traditional medicinal use. The Committee on Herbal Medicinal Products (HMPC) of the EMA released a monograph concluding that milk thistle preparations are safe and efficient to be used. In the EU, milk thistle preparations are regulated and introduced on the market according to their medical or food intended use. Plant-based health claims have not been evaluated by EFSA since 2010.

• China — Milk thistle has been included in the Pharmacopoeia of the People's Republic of China with defined quality standards.

• Other Regions — Silymarin has been approved in different doses for the treatment or adjuvant therapy for liver disorders by regulatory authorities of different countries, but has still been used primarily as a dietary supplement in the US despite its high sales.

Testing protocols must adhere to international standards including USP (Powdered Milk Thistle Extract monograph), European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

99$/KG

89$/KG